Your browser doesn't support javascript.
loading
Postmastectomy Breast Reconstruction is Safe in Patients on Chronic Anticoagulation.
Yan, Maria; Kuruoglu, Doga; Boughey, Judy C; Manrique, Oscar J; Tran, Nho V; Harless, Christin A; Martinez-Jorge, Jorys; Nguyen, Minh-Doan T.
Afiliação
  • Yan M; Division of Plastic and Reconstructive Surgery, Mayo Clinic, Rochester, Minnesota.
  • Kuruoglu D; Division of Plastic and Reconstructive Surgery, Mayo Clinic, Rochester, Minnesota.
  • Boughey JC; Division of Breast Melanoma Surgical Oncology, Mayo Clinic, Rochester, Minnesota.
  • Manrique OJ; Division of Plastic Surgery, University of Rochester, Rochester, New York.
  • Tran NV; Division of Plastic and Reconstructive Surgery, Mayo Clinic, Rochester, Minnesota.
  • Harless CA; Division of Plastic and Reconstructive Surgery, Mayo Clinic, Rochester, Minnesota.
  • Martinez-Jorge J; Division of Plastic and Reconstructive Surgery, Mayo Clinic, Rochester, Minnesota.
  • Nguyen MT; Division of Plastic and Reconstructive Surgery, Mayo Clinic, Rochester, Minnesota.
Arch Plast Surg ; 49(3): 346-351, 2022 May.
Article em En | MEDLINE | ID: mdl-35832147
ABSTRACT
Background Postmastectomy breast reconstruction (PMR) increases patient satisfaction, quality of life, and psychosocial well-being. There is scarce data regarding the safety of PMR in chronic anticoagulated patients. Perioperative complications can reduce patient satisfaction; therefore, it is important to elucidate the safety of PMR in these patients. Methods A retrospective case-control study of patients who underwent PMR with implants and were on chronic anticoagulation was performed at our institution. Inclusion criteria were women ≥ 18 years old. Exclusion criteria included autologous reconstructions, lumpectomy, and oncoplastic procedures. Two controls for every one patient on anticoagulation were matched by age, body mass index, radiotherapy, smoking history, type of reconstruction, time of reconstruction, and laterality. Results From 2009 to 2020, 37 breasts (20 patients) underwent PMR with implant-based reconstruction and were on chronic anticoagulation. A total of 74 breasts (40 patients) who had similar demographic characteristics to the cases were defined as the control group. Mean age for the case group was 53.6 years (standard deviation [SD] = 16.1), mean body mass index was 28.6 kg/m 2 (SD = 5.1), and 2.7% of breasts had radiotherapy before reconstruction and 5.4% after reconstruction. Nine patients were on long-term warfarin, six on apixaban, three on rivaroxaban, one on low-molecular-weight heparin, and one on dabigatran. The indications for anticoagulation were prior thromboembolic events in 50%. Anticoagulated patients had a higher risk of capsular contracture (10.8% vs. 0%, p = 0.005). There were no differences regarding incidence of hematoma (2.7% vs. 1.4%, p = 0.63), thromboembolism (5% vs. 0%, p = 0.16), reconstructive-related complications, or length of hospitalization (1.6 days [SD = 24.2] vs. 1.4 days [SD = 24.2], p = 0.85). Conclusion Postmastectomy implant-based breast reconstruction can be safely performed in patients on chronic anticoagulation with appropriate perioperative management of anticoagulation. This information can be useful for preoperative counseling on these patients.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article